The Compounding Litigation Map: Every Novo Nordisk and Lilly Lawsuit Against GLP-1 Compounders | SourceGLP-1
June 12, 2026
The Compounding Litigation Map: Every Novo Nordisk and Lilly Lawsuit Against GLP-1 Compounders
Amycretin: Novo's Next-Gen Amylin/GLP-1 Co-Agonist — Phase 2 Data and Pipeline Position | SourceGLP-1
June 11, 2026
Amycretin: Novo's Next-Gen Amylin/GLP-1 Co-Agonist — Phase 2 Data and Pipeline Position
Survodutide: Boehringer Ingelheim's GLP-1/Glucagon Dual Agonist | SourceGLP-1
June 11, 2026
Survodutide (BI 456906) is Boehringer Ingelheim's investigational GLP-1/glucagon dual agonist. Phase 2 data showed ~19% weight loss at 46 weeks. MASH indication prioritize
Pemvidutide: The Muscle-Sparing Dual Agonist With MASH Breakthrough Designation | SourceGLP-1
June 10, 2026
Pemvidutide is a GLP-1/glucagon dual agonist developed by Altimmune that received FDA Breakthrough Therapy designation for MASH in January 2026. Its glucagon-mediated fat oxidation
Medicare GLP-1 Coverage Economics: What the $50 Copay Actually Means | SourceGLP-1
June 10, 2026
The Medicare GLP-1 Bridge program ($50/month copay, July 2026) represents the largest government investment in obesity pharmacotherapy. Cost-benefit analysis with CBO projections a
GLP-1 Muscle Loss: What the 2026 Data Actually Shows | SourceGLP-1
June 09, 2026
Three major 2026 publications reframe the GLP-1 muscle loss debate: relative muscle mass improves, liver mass loss exceeds muscle loss, and mitochondrial proteins increase. Evidenc
GLP-1 Manufacturing at Scale: How Lilly and Novo Are Meeting Demand in 2026 | SourceGLP-1
June 09, 2026
Both Eli Lilly and Novo Nordisk have committed billions to GLP-1 manufacturing expansion. How the production scale-up is progressing, what it means for supply and pricing, and the
What Happens When You Stop GLP-1 Medications: The Weight Regain Data | SourceGLP-1
June 08, 2026
STEP-1 extension data: two-thirds of weight regained within 1 year of stopping semaglutide. Cardiometabolic improvements reversed proportionally. Evidence-based discontinuation ana
Compounded Semaglutide Stability: What the Chemistry Says | SourceGLP-1
June 08, 2026
Compounded semaglutide stability: beyond-use dating requirements, peptide degradation pathways, storage conditions, and why 503B outsourcing facilities provide more reliable stabil
GLP-1 Medications and Breast Cancer: The Emerging Protective Signal | SourceGLP-1
June 07, 2026
Emerging May 2026 data suggests GLP-1 medications may be associated with improved breast cancer outcomes. Observational evidence, biological rationale, and research limitations ass
GLP-1 Medications and the Brain: The Emerging Neurodegeneration Data | SourceGLP-1
June 07, 2026
GLP-1 receptors are expressed throughout the brain. Emerging evidence suggests neuroprotective effects in Alzheimer's disease, Parkinson's disease, and age-relate
BELIEVE Trial: Bimagrumab + Semaglutide Achieves 22.1% Weight Loss With 92.8% From Fat Mass | SourceGLP-1
June 06, 2026
The BELIEVE trial (NCT05616013), published in Nature Medicine March 2026, is the first randomized trial to demonstrate pharmacological muscle preservation during GLP-1 therapy. 507
TRIUMPH-1 Phase 3 Topline Results: Retatrutide Achieves 28.3% Weight Loss at 80 Weeks | SourceGLP-1
June 06, 2026
Full analysis of TRIUMPH-1 Phase 3 topline data: retatrutide 4mg/9mg/12mg efficacy, cardiometabolic outcomes, safety signals, and regulatory timeline.
Retatrutide vs. Tirzepatide vs. Semaglutide: Phase 3 Efficacy and Safety Data Compared | SourceGLP-1
June 05, 2026
Cross-trial comparison of retatrutide (TRIUMPH-1), tirzepatide (SURMOUNT-1), and semaglutide (STEP-1) Phase 3 data. Efficacy, safety, and cardiometabolic outcomes.
The Oral GLP-1 Landscape in 2026: Three Drugs, Three Strategies, One Goal | SourceGLP-1
June 05, 2026
Oral semaglutide, orforglipron (Foundayo), and amycretin compared. Efficacy, pricing, mechanism, and what the pill revolution means for GLP-1 access.
GLP-1 Safety Signals in 2026: A Comprehensive Evidence Review | SourceGLP-1
June 04, 2026
Complete review of GLP-1 safety signals: pancreatitis, thyroid cancer, gastroparesis, NAION, hair loss, ED, and gallbladder events. Evidence quality assessed.
GLP-1 Market Intelligence: Tirzepatide Projected as World's Top-Selling Drug in 2026 | SourceGLP-1
June 04, 2026
Tirzepatide projected at $45B in 2026 sales. Semaglutide at $39.5B. Market analysis of the $84.5B GLP-1 pharmaceutical landscape.
GLP-1 Insurance Coverage in 2026: What's Changed and What to Expect | SourceGLP-1
June 03, 2026
GLP-1 insurance coverage timeline 2026: Medicare Bridge $50/month copay, Medicaid expansion, commercial plan trends, and the prior authorization playbook.
GLP-1 Medications and Addiction: The Unexpected Data on Alcohol, Nicotine, and Substance Use | SourceGLP-1
June 03, 2026
GLP-1 medications reduce alcohol cravings by 41%, decrease smoking urge, and show signals across multiple substance use disorders. Complete evidence review.
Zepbound Vial Pricing Decoded: Every Dose, Every Channel | SourceGLP-1
June 03, 2026
Complete decoded breakdown of Zepbound vial pricing by dose, channel, and commercial structure.
Zepbound FDA Approval for Sleep Apnea: The Complete SURMOUNT-OSA Data | SourceGLP-1
June 03, 2026
On December 20, 2024, the FDA approved Zepbound as the first-ever medication for obstructive sleep apnea. Here's what the SURMOUNT-OSA trial actually showed.
Weight Regain After Stopping GLP-1s: The Complete Clinical Trial Data | SourceGLP-1
June 03, 2026
What happens when you stop semaglutide or tirzepatide? We analyze the STEP 1 extension, SURMOUNT-4, and real-world data on weight regain and prevention strategies.
Wegovy HD 7.2mg: The Data Behind the Strongest Semaglutide Dose | SourceGLP-1
June 03, 2026
FDA approved semaglutide 7.2mg on May 13, 2026. STEP UP trial: 20.7% weight loss, 1 in 3 achieving 25%+. The sourced data breakdown.
The $349 Wegovy Price Cut: A Full Pricing Timeline | SourceGLP-1
June 03, 2026
Complete timeline of Wegovy's $349 NovoCare cash-pay price cut and subsequent market changes.
TrumpRx Explained: The Government Portal Reshaping GLP-1 Access | SourceGLP-1
June 03, 2026
Complete explainer on the TrumpRx federal drug portal and what it means for GLP-1 access.
Tirzepatide vs Semaglutide 2026: SURMOUNT-5 Head-to-Head Comparison | SourceGLP-1
June 03, 2026
Tirzepatide vs semaglutide compared on the SURMOUNT-5 NEJM 2025 head-to-head data: 20.2% vs 13.7% weight loss, side effects, dose ladders, current 2026 cash prices, and who should
Tirzepatide vs. Semaglutide: Head-to-Head Comparison | SourceGLP-1
June 03, 2026
A comprehensive comparison of Mounjaro/Zepbound (tirzepatide) vs Ozempic/Wegovy (semaglutide). Weight loss data, side effects, mechanisms, and which might work better for you.
Tirzepatide 101: The Complete Beginner's Guide | SourceGLP-1
June 03, 2026
Everything you need to know about tirzepatide (Mounjaro/Zepbound). How it works, dosing, what to expect, and why it's different from semaglutide.
SYNERGY-NASH: Tirzepatide's Liver Disease Breakthrough | SourceGLP-1
June 03, 2026
Deep evidence review of the SYNERGY-NASH trial of tirzepatide for MASH/NASH liver disease.
SURPASS-CVOT: Tirzepatide's Diabetic Heart Disease Data | SourceGLP-1
June 03, 2026
Deep evidence review of the SURPASS-CVOT trial of tirzepatide for diabetic cardiovascular disease.
SURMOUNT-OSA: Tirzepatide and Sleep Apnea Reversal | SourceGLP-1
June 03, 2026
Evidence review of SURMOUNT-OSA, the trial that made tirzepatide the first drug FDA-approved for OSA.
Sulfur Burps Explained: The GI Science Behind GLP-1 Side Effects | SourceGLP-1
June 03, 2026
Why do Ozempic and Wegovy cause rotten egg burps? The science of delayed gastric emptying, hydrogen sulfide, and evidence-based relief strategies.
Should You Stock Up on Compounded GLP-1s Before the June 29 Deadline? | SourceGLP-1
June 03, 2026
The FDA's comment deadline is June 29, 2026. Should patients order extra compounded semaglutide now? We source the facts on shelf life, legality, and risk.
The STEP Program: Every Semaglutide Weight-Loss Trial | SourceGLP-1
June 03, 2026
Evidence review of the complete STEP clinical trial program for semaglutide weight management.
STEP HFpEF: GLP-1s for Obesity-Related Heart Failure | SourceGLP-1
June 03, 2026
Evidence review of the STEP HFpEF trial of semaglutide for heart failure with preserved ejection fraction.
State Attorneys General vs. GLP-1 Telehealth: Active Investigations | SourceGLP-1
June 03, 2026
Active state AG investigations into GLP-1 telehealth companies and what they mean for the industry.
How Much Is Tirzepatide on Sprout Health? Pricing Breakdown for 2026 | SourceGLP-1
June 03, 2026
Sprout Health tirzepatide pricing for 2026: what you'll pay per month, what's included, how it compares to other providers, and whether it's worth it.
Sprout Health Review 2026: Is It Legit? The Honest Verdict | Source GLP-1
June 03, 2026
Sprout Health GLP-1 review with BBB, Trustpilot, and customer complaint data. Compounded semaglutide $249/mo, tirzepatide $299/mo. Honest pros, cons, and who it actually fits.
Sprout Health GLP-1 Review 2026: Pricing, Pharmacies, Pros, Cons & What They Don't Tell You | SourceGLP-1
June 03, 2026
Independent Sprout Health review. Compounded semaglutide $249/month, tirzepatide $299/month. Partner pharmacies, state availability, price-lock guarantee, customer review patterns,
Sprout Health GLP-1 Cost: Complete 2026 Pricing Breakdown | Source GLP-1
June 03, 2026
Sprout Health GLP-1 pricing: compounded semaglutide $249/mo, tirzepatide $299/mo. First-month promos, 3-month plans, state availability, and price-lock explained. Sourced.
Where to Source Legit GLP-1 This Summer — And What to Avoid (2026) | Source GLP-1
June 03, 2026
How to find legitimate GLP-1 medications online in 2026. Red flags to watch for, verified providers, and how to avoid scams in the booming weight loss market.
GLP-1 Side Effects Timeline: Week-by-Week What to Expect | SourceGLP-1
June 03, 2026
A week-by-week guide to Ozempic and Wegovy side effects. When nausea peaks, when it fades, and what symptoms warrant calling your doctor.
Semaglutide vs Tirzepatide: Which One Should You Pick? | SourceGLP-1
June 03, 2026
Head-to-head comparison of semaglutide and tirzepatide. Efficacy, side effects, cost, and who each medication works best for.
Semaglutide vs. Tirzepatide: Head-to-Head Data, Cost, and Access in 2026 | SourceGLP-1
June 03, 2026
SURMOUNT-5 trial data compared: tirzepatide achieved 20.2% weight loss vs semaglutide's 13.7% at 72 weeks. Full breakdown of cost, side effects, and access.
Semaglutide vs Bariatric Surgery: STEP and STAMPEDE Outcomes Compared | Source GLP-1
June 03, 2026
Bariatric surgery delivers 25–35% sustained weight loss; semaglutide delivers ~15%; tirzepatide ~21%. Surgery wins on magnitude. Medications win on invasiveness and reversibility
Semaglutide Shortage Status: Current FDA Tracker (April 2026) | Source GLP-1
June 03, 2026
The FDA declared the semaglutide shortage resolved on February 21, 2025. The compounding pathway closed in April–May 2025. Here's the current status, the litigation that's still
The Patent Cliff: When Generic Semaglutide Actually Arrives | SourceGLP-1
June 03, 2026
Full timeline for when generic semaglutide actually arrives at U.S. retail pharmacies.
Semaglutide Approved for MASH: What the ESSENCE Trial Showed | SourceGLP-1
June 03, 2026
FDA approves semaglutide for MASH with liver fibrosis. Breaking down the ESSENCE trial data: 63% resolution of steatohepatitis, 37% fibrosis improvement.
FDA Approves Semaglutide for MASH: The ESSENCE Trial Results | SourceGLP-1
June 03, 2026
Wegovy becomes the first GLP-1 approved for fatty liver disease (MASH). ESSENCE trial showed 63% achieved resolution of liver inflammation vs 34% on placebo.
JAMA 2025: Semaglutide Reduces Alcohol Consumption in First Randomized Trial | SourceGLP-1
June 03, 2026
The first placebo-controlled trial of semaglutide for alcohol use disorder shows reduced drinking, cravings, and heavy drinking days. Full study breakdown.
Semaglutide 101: The Complete Beginner's Guide | SourceGLP-1
June 03, 2026
Everything you need to know about semaglutide. How it works, what to expect, dosing, side effects, and results from clinical trials.
SELECT Trial: Wegovy Reduces Heart Attacks and Strokes by 20% | SourceGLP-1
June 03, 2026
The SELECT trial proved semaglutide reduces cardiovascular events in people without diabetes. Full analysis of the landmark study that changed GLP-1 treatment.
The SELECT Trial: How GLP-1s Became Heart Medications | SourceGLP-1
June 03, 2026
Complete analysis of the SELECT trial that proved semaglutide reduces heart attacks, strokes, and cardiovascular death in people without diabetes. 17,604 patients, 20% risk reducti
SELECT Trial Five-Year Follow-Up: Cardiovascular Outcomes Data | SourceGLP-1
June 03, 2026
Deep evidence review of the SELECT cardiovascular outcomes trial and its extended follow-up.
The Ro, Hims, LifeMD, WeightWatchers Partnership Map | SourceGLP-1
June 03, 2026
Complete map of the authorized telehealth partnerships for Wegovy and Zepbound distribution.
Retatrutide: The "Triple G" Drug Showing 28.7% Weight Loss | SourceGLP-1
June 03, 2026
Retatrutide is Lilly's triple hormone agonist showing the highest weight loss yet—28.7% in Phase 3 trials. Here's everything we know about the Triple G drug.
Retatrutide Phase 3 Results: 28.7% Weight Loss with Triple Agonist | SourceGLP-1
June 03, 2026
Eli Lilly's retatrutide achieves 28.7% weight loss (71 lbs) in TRIUMPH-4 Phase 3 trial. First triple-agonist GLP-1/GIP/glucagon results analyzed.
Retatrutide Phase 2: The 24% Weight Loss Molecule | SourceGLP-1
June 03, 2026
Evidence review of retatrutide phase 2 data and the TRIUMPH phase 3 program.
Retatrutide: The Triple Agonist Approaching Bariatric Surgery Results | SourceGLP-1
June 03, 2026
Complete analysis of Eli Lilly's retatrutide (LY3437943): 28.7% weight loss in TRIUMPH trials, how triple agonism works, side effects including dysesthesia, and 2027 approval timel
Retail Pharmacy GLP-1 Pricing: Costco, Walmart, CVS | SourceGLP-1
June 03, 2026
Complete reference on retail pharmacy cash-pay pricing for GLP-1 medications in 2026.
The Reddit Study: What 410,000 GLP-1 Posts Say About Real-World Side Effects | SourceGLP-1
June 03, 2026
Penn researchers analyzed 410,198 Reddit posts with AI to surface GLP-1 side effects missing from clinical trials. Full source file with primary citations.
How Much Protein Do You Need on GLP-1 Medications? A Complete Guide | SourceGLP-1
June 03, 2026
Protein requirements on Ozempic and Wegovy: research-based recommendations, how to hit targets when appetite is suppressed, and why it matters for muscle.
PBM Rebate Economics: Why Your Copay Isn't the List Price | SourceGLP-1
June 03, 2026
Explainer on PBM rebate economics and how they affect GLP-1 copays vs cash-pay pricing.
Can You Get Ozempic Without a Prescription? (Source: No) | SourceGLP-1
June 03, 2026
Ozempic requires a valid prescription in the US. Here's why, what the legal requirements are, and how to access it legitimately.
The Ozempic Plateau: Why Weight Loss Stalls and What Actually Works | SourceGLP-1
June 03, 2026
Weight loss plateaus on GLP-1 medications are normal, typically hitting around week 60. Here's the science behind why it happens and evidence-based strategies to break through.
The Ozempic Thyroid Cancer Warning: What the Black Box Actually Means | SourceGLP-1
June 03, 2026
GLP-1 medications carry a black box warning for thyroid cancer based on rodent studies. Here's what the research shows about actual risk in humans.
Ozempic Side Effects Timeline: Week-by-Week What to Expect | SourceGLP-1
June 03, 2026
A week-by-week guide to GLP-1 side effects. When nausea starts, peaks, and resolves. When to call your doctor. What's normal vs. concerning.
The Ozempic Plateau Explained: Why Weight Loss Stalls | Source GLP-1
June 03, 2026
Plateaus on semaglutide are not failures — they are the well-documented endpoint observed in STEP 1, STEP 5, and SELECT. Here's what the trial data show about when weight loss fl
"Ozempic Penis" — What Urologists Actually Say | SourceGLP-1
June 03, 2026
Men on semaglutide report their penis 'got bigger.' We talked to Yale urologists and reviewed the research. Here's what the evidence actually shows.
Why Ozempic Doesn't Work for Everyone: The Non-Responder Problem | SourceGLP-1
June 03, 2026
Up to 15-23% of people don't lose significant weight on GLP-1 medications. Here's what the science says about non-responders and what options exist.
Ozempic Approved for Kidney Disease: The FLOW Trial Breakthrough | SourceGLP-1
June 03, 2026
FDA approves semaglutide for chronic kidney disease in type 2 diabetes. FLOW trial showed 24% reduced risk of kidney failure. Full trial analysis.
Loose Skin After GLP-1 Weight Loss: Ozempic Face, Body, and What to Expect | SourceGLP-1
June 03, 2026
Will Ozempic cause loose skin? We explain 'Ozempic face,' skin laxity after rapid weight loss, who's at risk, and treatment options.
"Ozempic Face": Why Weight Loss Can Age Your Face and What You Can Do | SourceGLP-1
June 03, 2026
Ozempic face refers to facial sagging and hollowing from rapid weight loss. Here's what causes it, who's at risk, and evidence-based prevention strategies.
"Ozempic Face" — Dermatologists Explain the Aging Effect | SourceGLP-1
June 03, 2026
Rapid GLP-1 weight loss can cause facial volume loss, sagging skin, and premature aging. Here's what dermatologists and plastic surgeons say—with data.
"Ozempic Dreams" — Why GLP-1 Users Report Vivid, Bizarre Dreams | SourceGLP-1
June 03, 2026
Thousands report strange, vivid dreams on semaglutide. Shopping with Clint Eastwood, robbing museums with celebrities. Here's the neuroscience and what Novo Nordisk says.
"Ozempic Babies": The Fertility Surprise Explained | SourceGLP-1
June 03, 2026
Why women on GLP-1 medications are reporting unexpected pregnancies. The science behind fertility restoration, birth control absorption, and what you need to know.
"Ozempic Babies": The Fertility Surprise Explained | SourceGLP-1
June 03, 2026
Why are women getting pregnant on Ozempic? We explain the science behind restored fertility, birth control concerns, and what the research shows.
"Ozempic Babies": How GLP-1s Affect Fertility and Birth Control | SourceGLP-1
June 03, 2026
The Ozempic baby boom is real. Here's the science behind why GLP-1 medications can boost fertility, potentially interfere with birth control, and what's known about pregnancy safet
Does Ozempic Kill Your Alcohol Cravings? (Source: Yes, Here's Why) | SourceGLP-1
June 03, 2026
Randomized trial data confirms semaglutide reduces alcohol consumption. The neuroscience of why GLP-1 drugs decrease drinking—verified with sources.
Orforglipron: The $200/Month Oral GLP-1 That Could Replace Injectables | SourceGLP-1
June 03, 2026
Eli Lilly's orforglipron: 14.7% weight loss in a daily pill, no fasting required, projected $200-350/month pricing. ATTAIN trial results and 2026 approval timeline.
Orforglipron: The Daily Oral GLP-1 Pill That Could Change Everything | SourceGLP-1
June 03, 2026
Orforglipron is Lilly's once-daily oral GLP-1 pill showing 12.4% weight loss in trials. FDA submission filed. What you need to know about this game-changer.
Orforglipron: The Next Oral GLP-1 and Why It Matters | SourceGLP-1
June 03, 2026
Eli Lilly's orforglipron has an FDA decision date of April 10, 2026. In head-to-head trials, it outperformed oral semaglutide on weight loss and blood sugar control.
Orforglipron: The Next Oral GLP-1 in the Pipeline | SourceGLP-1
June 03, 2026
Eli Lilly's orforglipron is a non-peptide oral GLP-1 with no food restrictions. Expected FDA decision by end of 2026. Here's what the Phase 3 data shows.
The Orforglipron ACHIEVE Trials: Oral GLP-1 Efficacy | SourceGLP-1
June 03, 2026
Evidence review of orforglipron's ACHIEVE and ATTAIN phase 3 trials for the first truly convenient oral GLP-1.
The GLP-1 Pill Is Here: What Oral Wegovy Means for You | SourceGLP-1
June 03, 2026
Oral Wegovy was approved December 2025 — the first GLP-1 pill for weight loss. Here's what the clinical data shows, what it costs, and how to get it.
Oral Wegovy at 5 Months: What the Real-World Data Shows | SourceGLP-1
June 03, 2026
Oral Wegovy launched January 2026 at $149/month. Five months in, here's what the early real-world data and patient experience reveal.
Oral vs Injectable Semaglutide: The Bioavailability Data | SourceGLP-1
June 03, 2026
Oral semaglutide (Rybelsus) has 0.4-1% bioavailability vs. 89% for injectable. Here's the complete pharmacokinetic comparison and what it means for efficacy.
Oral Semaglutide (Rybelsus) vs Oral Wegovy: The Dose That Changed Everything | SourceGLP-1
June 03, 2026
Rybelsus maxes out at 14mg for diabetes. Oral Wegovy delivers 25mg for weight loss. Same molecule, radically different results. Here's the clinical comparison.
Oral GLP-1s Just Hacked the Brain's Pleasure Center — And Scientists Are Freaking Out | SourceGLP-1
June 03, 2026
An NIH-funded Nature study found oral GLP-1 drugs like Foundayo reach the central amygdala to suppress pleasure-based eating through a separate mechanism from injectables.
Novo Nordisk Q1 2026 Earnings: What They Reveal About GLP-1 Supply | SourceGLP-1
June 03, 2026
Novo Nordisk's latest earnings paint a clear picture of GLP-1 supply, demand, and pricing strategy. Here's what the financial data means for patients.
Novo Nordisk's 111+ Trademark Lawsuits Against Compounders: Full Tracker | SourceGLP-1
June 03, 2026
Novo Nordisk has filed 111+ lawsuits against compounding pharmacies and telehealth companies. Track every case, outcome, and what it means for compounded semaglutide.
SEC Filings Reveal: What Novo and Lilly Told Investors About 2026 Pricing | SourceGLP-1
June 03, 2026
What Novo Nordisk and Eli Lilly's SEC filings say about 2026 GLP-1 pricing and competition.
2026 Revenue Forecasts: Novo vs. Lilly by the Numbers | SourceGLP-1
June 03, 2026
2026 GLP-1 revenue forecasts for Novo Nordisk and Eli Lilly, with Wegovy and Zepbound breakdowns.
The Novo–Hims Settlement: How the Compounded Copycat War Ended | SourceGLP-1
June 03, 2026
Inside the March 9, 2026 Novo Nordisk-Hims & Hers settlement that ended the compounded semaglutide war.
Next-Gen GLP-1s: Retatrutide, Amycretin & Orforglipron Trial Data | SourceGLP-1
June 03, 2026
Retatrutide delivers 28.7% weight loss in Phase 3. Amycretin hits 22%. Orforglipron offers needle-free daily pill. Complete trial data on what's coming next.
$50 GLP-1s for Medicare Patients Start July 1 — Here's Exactly Who Qualifies and What's Covered | SourceGLP-1
June 03, 2026
The Medicare GLP-1 Bridge launches July 2026 offering Foundayo, Wegovy, and Zepbound KwikPen for $50/month. Complete eligibility guide with plan types and formulation details.
The Medicare Price Negotiation: Unpacking the 71% Ozempic Discount | SourceGLP-1
June 03, 2026
Full breakdown of the Medicare 71% Ozempic discount and what it means for 2027 GLP-1 access.
International GLP-1 Price Arbitrage in 2026 | SourceGLP-1
June 03, 2026
International GLP-1 price arbitrage analysis — what channels remain economically meaningful in 2026.
Injectable vs Oral vs Sublingual GLP-1: Which Form is Right for You? | SourceGLP-1
June 03, 2026
GLP-1 delivery methods compared. Needles vs pills vs drops. Pros, cons, and which format fits your lifestyle.
HRSA 340B and GLP-1s: The Hospital Pricing Loophole | SourceGLP-1
June 03, 2026
How the HRSA 340B program creates a hidden GLP-1 pricing channel through hospitals and FQHCs.
How to Get Started on a GLP-1 Medication in 2026 | SourceGLP-1
June 03, 2026
Step-by-step guide to starting GLP-1 treatment in 2026. Eligibility, telehealth vs PCP, injectable vs oral, insurance vs cash-pay, and what to expect in your first week.
How to Get GLP-1 Through Telehealth (Step-by-Step) | SourceGLP-1
June 03, 2026
The exact process from quiz to delivery. How telehealth GLP-1 prescriptions work, what to expect, and how long it takes.
Women Lose 60% More Weight on GLP-1s Than Men | SourceGLP-1
June 03, 2026
A Johns Hopkins analysis published in JAMA Internal Medicine found women lost an average of 11% body weight versus 7% for men. But the drugs work equally w
Who Should NOT Take GLP-1 Medications | SourceGLP-1
June 03, 2026
GLP-1 medications aren't for everyone. Contraindications, cautions, and conditions that may make these drugs inappropriate.
When to Stop GLP-1 Medications: Surgery, Pregnancy, Side Effects & Plateaus | SourceGLP-1
June 03, 2026
Complete guide on when to pause or stop semaglutide and tirzepatide. Covers pre-surgery protocols, pregnancy planning, adverse events, weight plateaus, and what happens when you st
What We Still Don't Know About GLP-1 Medications | SourceGLP-1
June 03, 2026
An honest look at the unanswered questions about GLP-1 medications. What the long-term data is missing and what we're still learning.
What to Eat on GLP-1 Medications: A Practical Diet Guide | SourceGLP-1
June 03, 2026
Practical nutrition guidance for Ozempic, Wegovy, and Mounjaro. What to eat, what to avoid, and how to maximize results while minimizing side effects.
The Ozempic Plateau: Why Weight Loss Stalls and What the Data Says | SourceGLP-1
June 03, 2026
Weight loss stopped on Ozempic? Research shows plateaus typically occur around 60-68 weeks. Here's why it happens and what to do about it.
GLP-1 Week 1 Meal Plan: What to Eat When Starting | SourceGLP-1
June 03, 2026
A practical 7-day meal plan for your first week on Ozempic, Wegovy, or Mounjaro. Nausea-friendly foods, protein priorities, and easy recipes.
GLP-1 Medications vs Bariatric Surgery: When to Choose What | SourceGLP-1
June 03, 2026
Comparing GLP-1 medications to bariatric surgery. Outcomes, reversibility, costs, and how to decide which approach is right for you.
GLP-1s and Vision Loss: The NAION Signal Explained | SourceGLP-1
June 03, 2026
What the research shows about semaglutide and NAION (nonarteritic anterior ischemic optic neuropathy). The JAMA study, FDA FAERS data, risk factors, and what you should watch for.
GLP-1s for Adults 75+: Special Considerations & Limited Evidence | SourceGLP-1
June 03, 2026
What we know (and don't know) about Ozempic, Wegovy, and tirzepatide in adults over 75. Trial exclusions, frailty concerns, and when GLP-1s may still make sense.
Triple Agonism Explained: Retatrutide and Beyond | SourceGLP-1
June 03, 2026
Retatrutide targets three receptors: GLP-1, GIP, and glucagon. How triple agonism could deliver even greater weight loss than current medications.
Traveling with GLP-1 Medications: Storage, TSA, and International Tips | SourceGLP-1
June 03, 2026
How to travel with Ozempic, Wegovy, or Mounjaro. TSA rules, temperature storage, and international considerations.
GLP-1 TikTok Myths Debunked: What's Actually True | SourceGLP-1
June 03, 2026
Separating fact from fiction on the most viral GLP-1 claims. What the science actually says about common Ozempic myths.
GLP-1s and Thyroid Cancer: What the Black Box Warning Actually Means | SourceGLP-1
June 03, 2026
The facts on semaglutide, tirzepatide and thyroid cancer risk. Understanding the FDA Black Box Warning, rodent studies vs human data, and who should not take GLP-1 medications.
GLP-1s & Testosterone: What the Studies Actually Show | SourceGLP-1
June 03, 2026
Research shows GLP-1 medications can increase testosterone levels in men with obesity by 18% on average. Here's the complete data on hormonal effects.
GLP-1 Taste Changes: Why Food Tastes Different on Ozempic | SourceGLP-1
June 03, 2026
Why does food taste different on semaglutide? New research shows GLP-1 drugs actually change taste bud gene expression and brain response to sweetness.
Switching GLP-1 Medications: When to Change and How to Do It Right | SourceGLP-1
June 03, 2026
Complete guide to switching from semaglutide to tirzepatide or between GLP-1 providers: when to switch, dose conversion, avoiding gaps, and what to expect.
Sulfur Burps on Ozempic: Causes, Prevention & Remedies | SourceGLP-1
June 03, 2026
The dreaded sulfur burps on GLP-1 medications. Why they happen, foods that trigger them, and proven strategies to reduce or eliminate this embarrassing side effect.
GLP-1 Success Stories: What the Clinical Data Actually Shows | SourceGLP-1
June 03, 2026
No fake testimonials — real clinical trial outcomes. From STEP to SURMOUNT to retatrutide, here's what the evidence says is possible with GLP-1 medications.
Stopping GLP-1 Medications: What to Expect and How to Minimize Regain | SourceGLP-1
June 03, 2026
What happens when you stop Ozempic or Zepbound? The STEP-1 extension data on weight regain, tapering strategies, and when you actually need to stop permanently.
GLP-1s for Smoking Cessation: What the Research Shows | SourceGLP-1
June 03, 2026
Can Ozempic help you quit smoking? We analyze the Annals of Internal Medicine study, active clinical trials, and the science behind GLP-1s and nicotine addiction.
Semaglutide and Smoking Cessation: What the Evidence Actually Shows | Source GLP-1
June 03, 2026
Two randomized trials. One positive pilot, one negative larger study. A 220,000-patient observational signal. Two new RCTs enrolling. Here's exactly what the smoking-cessation evid
SURMOUNT-OSA: Tirzepatide Cuts Sleep Apnea Severity by 50-60% | SourceGLP-1
June 03, 2026
Tirzepatide dramatically reduced sleep apnea severity in obese patients, potentially offering an alternative to CPAP. NEJM results show up to 63% AHI reduction.
FDA Approves Zepbound for Sleep Apnea: A Historic First | SourceGLP-1
June 03, 2026
Tirzepatide becomes the first medication ever approved to treat obstructive sleep apnea. What the SURMOUNT-OSA trial showed and what it means for 30 million Americans.
GLP-1 Side Effect Survival Guide: What Actually Helps | SourceGLP-1
June 03, 2026
Practical, evidence-based strategies for managing nausea, constipation, and other common GLP-1 side effects. What works and what doesn't.
Ozempic and Shopping Addiction: The Viral Reports Explained | SourceGLP-1
June 03, 2026
GLP-1 users report reduced compulsive shopping. No studies exist, but the dopamine science is intriguing. We separate anecdotes from theory.
Ozempic Killed My Shopping Addiction: The Retail Therapy Effect | SourceGLP-1
June 03, 2026
People report their urge to shop has vanished on GLP-1 medications. Why dopamine-driven retail therapy may be the latest 'addiction' these drugs affect.
GLP-1s for Shift Workers: Injection Timing & Irregular Schedules | SourceGLP-1
June 03, 2026
When to inject Ozempic or Mounjaro with irregular work hours. Practical guidance for nurses, factory workers, and anyone with rotating or night shifts.
How Long Do GLP-1 Medications Actually Last? Complete Shelf Life Guide | SourceGLP-1
June 03, 2026
Compounded semaglutide lasts 28-90 days. Brand-name Ozempic: 24 months. Oral Wegovy: no refrigeration needed. A sourced storage and shelf life reference.
GLP-1 Reviews: What Patients Actually Report About Weight Loss in 2026 | SourceGLP-1
June 03, 2026
Are GLP-1 medications legit? We reviewed the clinical trial data, real patient outcomes, and what to realistically expect from semaglutide and tirzepatide for weight loss.
1 in 10 People May Be Resistant to GLP-1 Drugs: The Stanford Discovery That Could Save You Thousands | SourceGLP-1
June 03, 2026
Stanford researchers found ~10% of people carry PAM gene variants that make GLP-1 drugs less effective. Here's what the science says and what it means for your treatment.
GLP-1 Receptors: Where They Are in Your Body | SourceGLP-1
June 03, 2026
GLP-1 receptors aren't just in your gut—they're in your brain, heart, kidneys, and more. Understanding receptor locations explains why these drugs have such wide-ranging effects.
Can Ozempic Help You Quit Smoking? What the Research Shows | SourceGLP-1
June 03, 2026
People are reporting they quit smoking on Ozempic without trying. The science behind GLP-1s and nicotine addiction, plus active clinical trials.
GLP-1s for Psoriasis: Can Weight Loss Improve Skin? | SourceGLP-1
June 03, 2026
Emerging evidence that GLP-1 weight loss may improve psoriasis severity. The obesity-inflammation-psoriasis connection and what patients are reporting.
The "Prozac Moment" for Addiction: Are GLP-1s a Revolution? | SourceGLP-1
June 03, 2026
Researchers are calling GLP-1 medications a potential paradigm shift for addiction treatment. What the 12+ clinical trials mean for the future of treating compulsive behaviors.
Protein on GLP-1s: How Much You Need to Preserve Muscle | SourceGLP-1
June 03, 2026
Protein requirements while on Ozempic, Wegovy, or Mounjaro. How much to eat, best sources, and strategies for when appetite is low.
GLP-1 Pricing Exposed: From API Cost to Your Pharmacy Bill | SourceGLP-1
June 03, 2026
The raw ingredient for a month of Ozempic costs under $50. So why does a prescription cost $1,000+? Breaking down the GLP-1 pricing chain with sources.
GLP-1s After Bariatric Surgery: Weight Regain, Safety & When It Makes Sense | SourceGLP-1
June 03, 2026
Can you use Ozempic or Wegovy after gastric sleeve or bypass? Evidence on weight regain treatment, safety considerations, and which post-bariatric patients are candidates.
GLP-1 Pipeline 2025-2027: Every Drug in Development Ranked | SourceGLP-1
June 03, 2026
Complete guide to next-gen GLP-1 drugs: CagriSema, Amycretin, Survodutide, VK2735, and more. Efficacy rankings, mechanisms, timelines, and how they compare to current medications.
What's Coming Next: The GLP-1 Pipeline for 2026 and Beyond | SourceGLP-1
June 03, 2026
Retatrutide, CagriSema, orforglipron, amycretin, and monthly injectables — the next generation of GLP-1 medications is coming. Here's every pipeline drug worth watching.
GLP-1 Pharmacokinetics: Why Weekly Dosing Works | SourceGLP-1
June 03, 2026
How semaglutide and tirzepatide stay active for a week when natural GLP-1 lasts only minutes. The science of half-life, albumin binding, and steady-state levels.
GLP-1s During Perimenopause: Hormones, Weight Gain & What Works | SourceGLP-1
June 03, 2026
How Ozempic and Wegovy work during perimenopause. Addressing hormonal weight gain, interactions with HRT, and what the research shows for women 40-55.
Ozempic & Wegovy for Teens: What Parents Need to Know (2025) | SourceGLP-1
June 03, 2026
FDA-approved GLP-1 medications for adolescents 12+. STEP TEENS trial data, safety considerations, and what the AAP recommends for childhood obesity treatment.
Pediatric GLP-1 Clinical Trials: STEP TEENS, Liraglutide & Tirzepatide Data | SourceGLP-1
June 03, 2026
Complete analysis of GLP-1 clinical trials in adolescents. STEP TEENS results, liraglutide pediatric data, and ongoing tirzepatide studies in children and teens.
GLP-1s and PCOS: Hormones, Fertility, and Real Results | SourceGLP-1
June 03, 2026
How semaglutide and tirzepatide are helping women with PCOS. The connection between insulin resistance, weight loss, and hormonal balance.
GLP-1 Drugs Show Promise for Parkinson's Disease: The Phase 2 Data | SourceGLP-1
June 03, 2026
Lixisenatide stopped motor symptom progression in early Parkinson's patients. Here's what the NEJM trial found and what's coming next.
GLP-1s and Pancreatitis: Signs, Risks, and What You Must Know | SourceGLP-1
June 03, 2026
The facts on semaglutide, tirzepatide and pancreatitis risk. Symptoms to watch for, who's at higher risk, and why you must stop permanently if it occurs.
GLP-1 Pancreatitis Risk: Reading the Trial Data Honestly | Source GLP-1
June 03, 2026
Two recent meta-analyses, two different headlines. A 51,346-patient-year semaglutide/tirzepatide dataset showing OR 0.99. A class-wide RR 1.44 that disappears when stratified by ba
Your Pancreas Already Makes Its Own Version of Ozempic | SourceGLP-1
June 03, 2026
Duke University scientists discovered that your pancreatic alpha cells — long thought to only produce glucagon — actually generate powerful amounts of GLP-
Ozempic vs Wegovy vs Mounjaro: Complete Comparison | SourceGLP-1
June 03, 2026
Head-to-head comparison of the major GLP-1 medications. Differences in weight loss, mechanism, dosing, side effects, and cost.
GLP-1s & Opioid Addiction: Penn State's Breakthrough Research | SourceGLP-1
June 03, 2026
Can semaglutide reduce opioid cravings? Penn State researchers found a 40% reduction in cravings in early trials. Here's the data from NIH-funded studies.
Why Some People Don't Respond to GLP-1s: The Non-Responder Problem | SourceGLP-1
June 03, 2026
10-15% of people don't respond well to GLP-1 medications. The science behind non-response and what to try next.
The Next Generation: GLP-1 Drugs in the Pipeline | SourceGLP-1
June 03, 2026
What's coming after Ozempic and Mounjaro? Retatrutide, orforglipron, and the next wave of obesity medications in clinical trials.
GLP-1 Muscle Loss: How Much Lean Mass Do Users Actually Lose? | SourceGLP-1
June 03, 2026
Comprehensive analysis of body composition data from STEP, SURMOUNT, and SURPASS trials. What DXA and MRI studies reveal about semaglutide and tirzepatide effects on lean mass.
GLP-1 Month by Month: What to Actually Expect | SourceGLP-1
June 03, 2026
A realistic timeline of your GLP-1 journey. What happens month 1, month 3, month 6, and beyond. Setting proper expectations.
GLP-1s and Menopause: HRT Interactions, Belly Fat & Weight Loss | SourceGLP-1
June 03, 2026
Complete guide to GLP-1 medications during and after menopause. HRT compatibility, targeting visceral fat, bone health monitoring, and cardiovascular benefits for postmenopausal wo
GLP-1s for MASH/Fatty Liver: Semaglutide's New FDA Approval | SourceGLP-1
June 03, 2026
Semaglutide received FDA approval for MASH in August 2025—the second drug ever approved for fatty liver disease. Phase 3 trial data, tirzepatide pipeline, and what it means.
May 2026 GLP-1 Market Report: Who's Still Standing After the FDA Crackdown | SourceGLP-1
June 03, 2026
A data-driven look at the GLP-1 telehealth market 14 months after the FDA's enforcement wave. Which providers survived, which didn't, and what the landscape looks like now.
Managing GLP-1 Nausea: Causes, Timeline, and What Actually Works | SourceGLP-1
June 03, 2026
Complete guide to managing nausea on semaglutide and tirzepatide: why it happens, how long it lasts, foods that help, medications like Zofran, and when to call your doctor.
Are GLP-1s the First Longevity Drugs? Every Proven (and Promising) Benefit, Ranked by Evidence | SourceGLP-1
June 03, 2026
From 6 FDA approvals to Alzheimer's prevention to addiction reduction: a complete, sourced scorecard of everything GLP-1 medications can — and can't — do in 2
GLP-1s and Kidney Protection: The FLOW Trial Breakthrough | SourceGLP-1
June 03, 2026
The FLOW trial was stopped early because semaglutide worked so well for kidney disease. What the data shows and what it means for millions with CKD.
FLOW Trial: Semaglutide Reduces Kidney Disease Progression by 24% | SourceGLP-1
June 03, 2026
The landmark FLOW trial showed semaglutide reduced major kidney events and death in diabetic kidney disease. Published in NEJM, stopped early for efficacy.
Keto + GLP-1s: Can You Combine Them? | SourceGLP-1
June 03, 2026
Is combining a ketogenic diet with Ozempic or Mounjaro safe and effective? Potential benefits, risks, and practical considerations for keto on GLP-1 medications.
GLP-1 Insurance Coverage 2025: Prior Authorization, Appeals & Savings Programs | SourceGLP-1
June 03, 2026
Navigate GLP-1 insurance in 2025: Medicare/Medicaid coverage by state, commercial plan restrictions, prior auth strategies, appeal tactics, and manufacturer savings programs up to
GLP-1 Insurance & Cost Guide: How to Actually Afford These Medications | SourceGLP-1
June 03, 2026
Strategies for getting GLP-1 medications covered by insurance, manufacturer savings programs, and alternative options when coverage fails.
GLP-1 Injection Technique: Sites, Rotation, and Pro Tips | SourceGLP-1
June 03, 2026
Complete guide to injecting semaglutide and tirzepatide: best injection sites, rotation patterns, preparation steps, and techniques for reducing pain and anxiety.
GLP-1 Drugs and Inflammation: Emerging Evidence for Autoimmune Conditions | SourceGLP-1
June 03, 2026
New data suggests GLP-1 drugs may reduce inflammation markers and autoimmune disease risk. Here's what the research shows for rheumatoid arthritis, psoriasis, and IBD.
GLP-1s and Heart Health: The SELECT Trial Results Explained | SourceGLP-1
June 03, 2026
The SELECT trial proved semaglutide reduces cardiovascular risk by 20% in people with obesity — even without diabetes. Here's what this landmark study means for patients.
GLP-1s and Heart Failure: The STEP-HFpEF Breakthrough | SourceGLP-1
June 03, 2026
Semaglutide dramatically improved symptoms and quality of life in heart failure patients. What the STEP-HFpEF trial means for millions living with HFpEF.
GLP-1s Reduced Heart Failure Severity by 40% | SourceGLP-1
June 03, 2026
Harvard and Brigham researchers found that GLP-1 medications improved heart failure with preserved ejection fraction by 40% — a condition that has historic
Hair Loss on GLP-1s: Every Study Analyzed | SourceGLP-1
June 03, 2026
Is GLP-1 hair loss real? We reviewed every FAERS analysis, cohort study, and dermatology paper. Here's what the data actually shows.
The Gut-Brain Axis: How GLP-1s Talk to Your Brain | SourceGLP-1
June 03, 2026
GLP-1 is a key messenger between your gut and brain. Understanding this communication system explains appetite, satiety, food noise, and why these medications work.
GLP-1s and Gout: Can Weight Loss Lower Uric Acid? | SourceGLP-1
June 03, 2026
GLP-1 medications may help gout by lowering uric acid levels. The obesity-gout connection, research on semaglutide and uric acid, and what patients report.
Ozempic for Gambling Addiction? What We Know (And Don't) | SourceGLP-1
June 03, 2026
Users report GLP-1s curb gambling and shopping urges. We analyze the anecdotal reports, dopamine science, and why no clinical trials exist yet.
Ozempic and Gambling: Why People Are Losing Interest in Casinos | SourceGLP-1
June 03, 2026
Reports of gambling urges disappearing on GLP-1 medications. The dopamine connection, viral stories, and what researchers think is happening.
GLP-1s and Gallbladder Problems: Gallstones, Symptoms, and What to Do | SourceGLP-1
June 03, 2026
Why rapid weight loss from semaglutide and tirzepatide increases gallstone risk. Symptoms to watch for, when to pause treatment, and whether you can restart after gallbladder surge
"Food Noise" Explained: The Neuroscience of Constant Hunger | SourceGLP-1
June 03, 2026
The constant mental chatter about food that vanishes on GLP-1 medications. What causes food noise, why some brains are louder, and how semaglutide silences it.
What Is "Food Noise"? How GLP-1s Quiet the Constant Chatter | SourceGLP-1
June 03, 2026
Food noise is the constant mental chatter about eating. Here's what it means, why some people have it, and how GLP-1 medications turn down the volume.
GLP-1s May Be the First Longevity Drugs in History | SourceGLP-1
June 03, 2026
At a 2025 Copenhagen conference, researchers from Novo Nordisk and Eli Lilly proposed something extraordinary: GLP-1 medications may be the first true anti
Why First-Gen GLP-1s Failed for Addiction (And Semaglutide Might Succeed) | SourceGLP-1
June 03, 2026
Exenatide and liraglutide trials for alcohol and cocaine showed mixed results. Why researchers think semaglutide's different pharmacology could change outcomes.
GLP-1s & Fertility: The "Ozempic Baby" Research | SourceGLP-1
June 03, 2026
What does science actually say about 'Ozempic babies'? Complete analysis of GLP-1 fertility research in PCOS, weight loss effects, birth control interactions, and pregnancy safety
GLP-1 Timeline: Every FDA Approval from 2005 to Today | SourceGLP-1
June 03, 2026
Complete chronological history of GLP-1 medication FDA approvals. From Byetta (2005) to today's expanded indications for cardiovascular protection, sleep apnea, and kidney disease.
GLP-1s and Fatty Liver Disease: The MASH Breakthrough | SourceGLP-1
June 03, 2026
Semaglutide shows remarkable results for MASH (fatty liver disease). What the ESSENCE trial found and why FDA granted Breakthrough Therapy designation.
Exercise on GLP-1 Medications: What Actually Matters | SourceGLP-1
June 03, 2026
How to exercise while on Ozempic, Wegovy, or Mounjaro. Why resistance training is essential and how to optimize your workouts.
Who Actually Qualifies for a GLP-1? FDA Criteria vs Insurance Rules vs Telehealth Reality | SourceGLP-1
June 03, 2026
GLP-1 eligibility breakdown: BMI requirements for Wegovy and Zepbound, FDA-approved criteria, what insurance actually demands, and why telehealth platforms approve at lower thresho
GLP-1s for Adults 65+: Complete Safety & Efficacy Guide | SourceGLP-1
June 03, 2026
Evidence-based guide to Ozempic, Wegovy, and other GLP-1s for seniors. Clinical trial data on adults 65+, muscle loss prevention, and special considerations from the SELECT and FLO
GLP-1 Drug Interactions: Insulin, Birth Control, Thyroid Meds & More | SourceGLP-1
June 03, 2026
Complete guide to GLP-1 medication interactions with insulin, sulfonylureas, birth control, levothyroxine, warfarin, and alcohol. Based on FDA labels and 2025 ADA guidelines.
GLP-1 Discontinuation: What Happens When You Stop Taking the Medication | SourceGLP-1
June 03, 2026
STEP 1 extension data shows most patients regain weight after stopping semaglutide. Here's what the research says about discontinuation.
Can GLP-1s Cause Depression? Examining the Evidence | SourceGLP-1
June 03, 2026
FDA and EMA investigations, FAERS data, WHO database analysis, and controlled studies on semaglutide and mental health. The complete picture with sources.
Ozempic Users Show Sharp Drops in Depression and Anxiety | SourceGLP-1
June 03, 2026
A major study published in The Lancet Psychiatry found that GLP-1 medication users had significantly fewer psychiatric hospital visits, less work absence d
GLP-1 Users Are 70% Less Likely to Develop Dementia | SourceGLP-1
June 03, 2026
A massive matched cohort study found GLP-1 medication users had a 70% reduced risk of developing dementia compared to non-users. The numbers are striking —
GLP-1s for Dementia: Why EVOKE Failed and What's Next | SourceGLP-1
June 03, 2026
The EVOKE trial of semaglutide for Alzheimer's didn't show benefit. But observational data suggests protection. Here's what we know about GLP-1s and brain health.
Counterfeit GLP-1 Medications: How to Spot Fakes | SourceGLP-1
June 03, 2026
Fake Ozempic and Wegovy are circulating. How to identify counterfeit GLP-1 medications and protect yourself from dangerous fakes.
Is $1,000/Month Worth It? The Real Cost-Benefit of GLP-1s | SourceGLP-1
June 03, 2026
An honest analysis of GLP-1 medication costs vs benefits. What the health economics research says about value.
Compounded GLP-1 Guide: 503A vs 503B, Quality Markers & Red Flags | SourceGLP-1
June 03, 2026
How to evaluate compounding pharmacies for semaglutide and tirzepatide. 503A vs 503B explained, PCAB accreditation, COA verification, FDA warning signs, and 15 questions to ask bef
GLP-1 Compounding Legal Status: What Happens Now That the Shortage Is Over | SourceGLP-1
June 03, 2026
The FDA declared semaglutide and tirzepatide shortages resolved. Here's what's still legal for compounding, the clinical difference exception, pending lawsuits, and what it means f
Is Compounded Semaglutide Safe? An Honest Assessment | SourceGLP-1
June 03, 2026
The truth about compounded GLP-1 medications. What we know about safety, quality concerns, and how to minimize risk.
Colon Cancer Patients on GLP-1s Were Half as Likely to Die Within 5 Years | SourceGLP-1
June 03, 2026
A UC San Diego study of 6,800+ colon cancer patients found that those taking GLP-1 medications had a 5-year mortality rate of 15.5% compared to 37.1% for n
GLP-1 Medications for Cocaine and Stimulant Addiction: Early Research | SourceGLP-1
June 03, 2026
Emerging research on semaglutide for cocaine and stimulant use disorders. What the science shows and what trials are underway.
GLP-1s for Cocaine Addiction: The Emerging Research | SourceGLP-1
June 03, 2026
Semaglutide reduced cocaine self-administration by 26% in rats and cocaine-seeking by 62%. We analyze the University of Gothenburg study and $2.7M UTHealth trial.
GLP-1 Clinical Trials Tracker 2025-2026: SURMOUNT, ACHIEVE, ATTAIN, REDEFINE, TRIUMPH, MARITIME, EVOKE | SourceGLP-1
June 03, 2026
Comprehensive database of major GLP-1 and incretin clinical trials. SURMOUNT-5 head-to-head, ACHIEVE-1 orforglipron, ATTAIN obesity results, REDEFINE CagriSema, TRIUMPH retatrutide
GLP-1s and Cirrhosis: Can They Help Advanced Liver Disease? | SourceGLP-1
June 03, 2026
GLP-1s show promise for fatty liver, but what about cirrhosis? Evidence, safety concerns, and why advanced liver disease requires special consideration.
GLP-1s and Chronic Pain: Can Weight Loss Reduce Pain? | SourceGLP-1
June 03, 2026
How GLP-1 weight loss medications may improve chronic pain conditions. The obesity-pain connection, anti-inflammatory effects, and what patients report.
From Shame to Prime Time: How Celebrities Changed GLP-1 Discourse | SourceGLP-1
June 03, 2026
When Oprah and other celebrities started talking openly about weight loss medications, the conversation changed. The cultural shift from secret shame to mainstream acceptance.
Semaglutide and Cannabis Use Disorder: The Molecular Psychiatry Study | SourceGLP-1
June 03, 2026
A study of 680,000+ patients found semaglutide users were 44-60% less likely to develop cannabis use disorder. We break down the Wang et al. 2024 findings.
GLP-1s and Cannabis: Study Shows 44% Reduction in Use | SourceGLP-1
June 03, 2026
A 2024 study found 44% lower cannabis use among patients on GLP-1 medications. What the research shows about marijuana, dopamine, and these drugs.
GLP-1s for Cancer Survivors: Safety, Benefits & Considerations | SourceGLP-1
June 03, 2026
Can cancer survivors safely use Ozempic or Wegovy? Evidence on GLP-1s after cancer treatment, weight management, and special considerations for cancer history.
GLP-1s May Reset the Cancer Immunity That Obesity Broke | SourceGLP-1
June 03, 2026
Duke Cancer Institute found that obesity shuts down the immune system's ability to fight cancer. In animal models, GLP-1 medications restored immune functi
Brain Receptor Map: Where GLP-1s Work in the Reward System | SourceGLP-1
June 03, 2026
GLP-1 receptors in the VTA, nucleus accumbens, and prefrontal cortex may explain why these drugs affect cravings. A visual guide to the neuroscience.
Every GLP-1's Boxed Warning Explained: MTC, MEN 2 & Thyroid C-Cell Tumors | SourceGLP-1
June 03, 2026
Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Rybelsus, and Saxenda all carry the same FDA boxed warning for thyroid C-cell tumors. What MTC and MEN 2 mean, who's contraindicated
Bodybuilders on GLP-1s: Muscle Preservation During Cuts | SourceGLP-1
June 03, 2026
Can you use Ozempic or tirzepatide while preserving muscle? Body composition data, cutting phase strategies, and what bodybuilders need to know about GLP-1s.
GLP-1s and the Brain: How These Drugs Change Your Mind | SourceGLP-1
June 03, 2026
GLP-1 medications access your brain directly. Understanding how they cross the blood-brain barrier explains appetite control, food noise reduction, and potential effects on addicti
GLP-1 Medications for Binge Eating Disorder | SourceGLP-1
June 03, 2026
Can Ozempic help binge eating disorder? The research on GLP-1 medications for BED and compulsive eating patterns.
7 Benefits of GLP-1 Medications Beyond Weight Loss | SourceGLP-1
June 03, 2026
GLP-1 medications do far more than help you lose weight. From heart protection to addiction reduction, here are 7 evidence-backed benefits you should know about.
Stopping GLP-1s Before Surgery: ASA & Multi-Society Guidance Explained (2024 Update) | SourceGLP-1
June 03, 2026
The American Society of Anesthesiologists' 2023 GLP-1 preoperative guidance was significantly updated in October 2024. What changed, who needs to hold their dose, who can continue,
GLP-1s and Atrial Fibrillation: Can Weight Loss Help AFib? | SourceGLP-1
June 03, 2026
Weight loss reduces AFib burden significantly. How GLP-1 medications may help atrial fibrillation through weight loss and beyond.
Athletes and GLP-1s: Performance Enhancement or Treatment? | SourceGLP-1
June 03, 2026
GLP-1 medications aren't banned by WADA, but athletes face unique considerations. Weight-class sports, muscle preservation, endurance effects, and the ethics debate.
Athletes on GLP-1s: Performance, Muscle, Recovery & What Pros Should Know | SourceGLP-1
June 03, 2026
How Ozempic and Wegovy affect athletic performance, muscle mass, endurance, and recovery. WADA status, professional athlete considerations, and sports-specific guidance.
GLP-1s and Anhedonia: The Pleasure-Killing Concern | SourceGLP-1
June 03, 2026
If GLP-1s dampen the reward system, could they reduce pleasure from everything—not just food and drugs? What we know about anhedonia risk.
The Anhedonia Question: Can GLP-1s Reduce Pleasure? | SourceGLP-1
June 03, 2026
Some people report reduced enjoyment of food, hobbies, and life on GLP-1 medications. What does the science say about this concern?
GLP-1 Drugs and Alzheimer's: Why the Largest Trials Failed Despite Promising Signs | SourceGLP-1
June 03, 2026
The EVOKE trials testing semaglutide for Alzheimer's disease failed their primary endpoints in November 2025. Here's what the data actually showed and what it means.
GLP-1s for Alcoholism: What the JAMA Study Actually Found | SourceGLP-1
June 03, 2026
The first randomized controlled trial of semaglutide for alcohol use disorder is here. We break down exactly what the February 2025 JAMA Psychiatry study found.
GLP-1s and Alcohol: The JAMA Study That Changed Everything | SourceGLP-1
June 03, 2026
A major JAMA Psychiatry study found 50-56% lower alcohol use disorder among GLP-1 patients. The science behind why Ozempic makes people drink less.
Drinking on GLP-1s: Alcohol Interactions, Risks, and What to Know | SourceGLP-1
June 03, 2026
Can you drink alcohol on Ozempic or Zepbound? The science on GLP-1 alcohol interactions: hypoglycemia risk, slower metabolism, reduced cravings, and liver protection research.
GLP-1 Medications Are More Affordable Than Ever in 2026 | SourceGLP-1
June 03, 2026
Complete GLP-1 pricing guide for 2026. Oral pills from $149/mo, injectable options from $150-350, cash-pay discounts, and every way to save on treatment.
GLP-1s Cut Addiction Risk Across ALL Substances — A First in Medicine | SourceGLP-1
June 03, 2026
A study of over 600,000 veterans found GLP-1 users were 15-20% less likely to misuse alcohol, opioids, cannabis, cocaine, or nicotine. No other drug has ev
The GLP-1 Starter Checklist: Everything to Have Ready | SourceGLP-1
June 03, 2026
Your complete prep list before starting GLP-1 treatment. Documents, supplies, questions to ask, and how to set yourself up for success.
17% Lower Cancer Risk: The JAMA Oncology Study Explained | SourceGLP-1
June 03, 2026
A study of 86,000+ adults found that GLP-1 medication users had 17% fewer new cancer diagnoses. The strongest signals were for endometrial cancer, ovarian
GLP-1 Provider Red Flags: What to Watch For | SourceGLP-1
June 03, 2026
How to spot sketchy GLP-1 telehealth providers. Red flags, warning signs, and what legitimate providers do differently.
GLP-1 Nausea: 8 Ways to Beat It | SourceGLP-1
June 03, 2026
Practical solutions for GLP-1 nausea. What causes it, when it improves, and 8 strategies that actually work.
GLP-1 in 5 Minutes: Everything You Need to Know | SourceGLP-1
June 03, 2026
The quick primer on GLP-1 medications. What they are, how they work, and whether they're right for you. No medical jargon, just facts.
What Disqualifies You From GLP-1? (And What Doesn't) | SourceGLP-1
June 03, 2026
GLP-1 eligibility explained. BMI requirements, medical conditions, and common myths busted. Find out if you qualify.
How Much Does GLP-1 Actually Cost? (2025 Price Breakdown) | SourceGLP-1
June 03, 2026
Real GLP-1 prices from real providers. What you'll actually pay for semaglutide and tirzepatide in 2025, including brand-name and compounded options.
GLP-1 Constipation: Solutions That Actually Work | SourceGLP-1
June 03, 2026
Practical fixes for GLP-1-related constipation. Why it happens and what to do about it.
The Science of Food Noise: Why GLP-1s Change How You Think About Eating | SourceGLP-1
June 03, 2026
What is 'food noise' and why do GLP-1 medications quiet it? The neuroscience of appetite signaling, reward pathways, and the experience patients describe as food freedom.
Food Noise Explained: The Brain Science Behind GLP-1 Medications | SourceGLP-1
June 03, 2026
fMRI brain imaging reveals how GLP-1 medications reduce food cravings and intrusive food thoughts. Primary research from Nature Medicine and clinical trials.
FLOW Trial: Semaglutide for Chronic Kidney Disease | SourceGLP-1
June 03, 2026
Evidence review of the FLOW trial of semaglutide for diabetic chronic kidney disease.
FLOW Trial Deep Dive: Semaglutide's 24% Kidney Disease Risk Reduction | SourceGLP-1
June 03, 2026
Complete analysis of the FLOW trial: semaglutide reduced major kidney events by 24%, CV events by 18%, and death by 20% in T2D patients with CKD. Full data and methodology.
Your First Week on GLP-1: What to Expect | SourceGLP-1
June 03, 2026
Day-by-day guide to your first week on GLP-1 medication. What's normal, what's not, and how to set yourself up for success.
All 50+ FDA Warning Letters (Sept 2025): Full Text & Analysis | SourceGLP-1
June 03, 2026
The FDA sent 50+ warning letters to GLP-1 compounders in September 2025. We've compiled every letter with analysis of what triggered enforcement.
Inside the FDA's March 2026 Warning Letters to 30 Compounded GLP-1 Telehealth Companies | SourceGLP-1
June 03, 2026
Full breakdown of the FDA's March 3, 2026 warning letters to 30 compounded GLP-1 telehealth companies.
FDA Warning Letters to GLP-1 Compounders: What Patients Need to Know | SourceGLP-1
June 03, 2026
The FDA issued 80+ warning letters to GLP-1 compounders in 2025-2026. What the letters say, who was targeted, and what it means for your treatment.
FDA Semaglutide Shortage Resolved: What It Means for Compounded GLP-1s in 2026 | SourceGLP-1
June 03, 2026
The FDA resolved the semaglutide shortage in February 2025. Here's the full timeline, what happened to compounding, and what your options are in 2026.
Why the FDA Removed Semaglutide From Shortage and What Happened Next | SourceGLP-1
June 03, 2026
Full timeline of how the FDA ended the semaglutide and tirzepatide shortages and reshaped the GLP-1 market.
FDA GLP-1 Approvals Timeline 2005-2026: Every Milestone From Byetta to Foundayo | SourceGLP-1
June 03, 2026
Complete FDA approval timeline for every GLP-1 medication: Byetta, Victoza, Tanzeum, Trulicity, Ozempic, Rybelsus, Wegovy, Mounjaro, Zepbound, Foundayo. Plus Zepbound OSA (Dec 2024
FDA Compounding Enforcement 2026: What's Actually Happening to 503A/503B Pharmacies | SourceGLP-1
June 03, 2026
FDA GLP-1 compounding enforcement actions in 2026. Warning letters, 503A vs 503B legal status, shortage declarations, and which pharmacies are still operating legally.
FDA Adverse Event Reports on Compounded GLP-1s: 2025 vs 2026 Comparison | SourceGLP-1
June 03, 2026
We analyzed FDA FAERS data on compounded semaglutide and tirzepatide adverse events. Here's how 2026 compares to 2025 — and what the numbers actually tell us.
FDA's 503B Bulks List Proposal: A Sourced Analysis | SourceGLP-1
June 03, 2026
The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from 503B compounding. Every claim sourced from the Federal Register and FDA statements.
The 455 Adverse Event Reports: What the FDA Compounded GLP-1 Data Actually Says | SourceGLP-1
June 03, 2026
The FDA cites 455+ adverse events from compounded semaglutide. What do the reports actually show? We source the data and provide context.
Fact Check: Does Zepbound Really Outperform Wegovy by 47%? | SourceGLP-1
June 03, 2026
Fact check of the SURMOUNT-5 head-to-head trial comparing tirzepatide to semaglutide.
Fact Check: The 'Ozempic Face' Phenomenon | SourceGLP-1
June 03, 2026
Fact check on 'Ozempic face' — what dermatologists actually say about facial volume changes on GLP-1s.
Fact Check: Is Oral Wegovy as Effective as the Injection? | SourceGLP-1
June 03, 2026
Fact check comparing oral Wegovy to injectable Wegovy for weight management.
Fact Check: Do GLP-1s Cause Thyroid Cancer? | SourceGLP-1
June 03, 2026
Fact check on the GLP-1 thyroid cancer black box warning and actual human risk data.
Fact Check: GLP-1 'Muscle Loss' Claims vs. Clinical Evidence | SourceGLP-1
June 03, 2026
Fact check on GLP-1 muscle loss claims versus the actual body composition trial data.
Fact Check: The Viral 'GLP-1 Birth Defect' Story | SourceGLP-1
June 03, 2026
Fact check on GLP-1 birth defect claims circulating on social media.
Fact Check: Claims About GLP-1 and Alcohol Use Disorder | SourceGLP-1
June 03, 2026
Fact check on GLP-1 medications for alcohol use disorder — what evidence supports the claim.
Fact Check: 'Compounded Tirzepatide Is Illegal Now' | SourceGLP-1
June 03, 2026
Fact check on the current legal status of compounded tirzepatide post-shortage.
Fact Check: Is Compounded Semaglutide 'Just as Effective' as Wegovy? | SourceGLP-1
June 03, 2026
Fact check on whether compounded semaglutide is really as effective as brand-name Wegovy.
Fact Check: The '1 in 5 Americans on GLP-1s' Headline | SourceGLP-1
June 03, 2026
Fact check of the viral '1 in 5 Americans on GLP-1s' statistic against actual survey data.
EVOKE Trial Results: Semaglutide and Cognitive Decline in Alzheimer's | Source GLP-1
June 03, 2026
Novo Nordisk's EVOKE and EVOKE+ trials — 3,808 participants across 40 countries, the largest GLP-1 neurodegeneration program ever conducted — returned negative on the primary c
EVOKE Trial Results: Semaglutide Fails Alzheimer's Test — But Prevention Story Remains | SourceGLP-1
June 03, 2026
Complete analysis of the EVOKE and EVOKE+ Phase 3 trials. Semaglutide didn't slow Alzheimer's progression, but biomarker data and observational studies suggest prevention potential
The Employer Health Plan Shift: Who's Still Covering GLP-1s | SourceGLP-1
June 03, 2026
Analysis of employer health plan coverage for GLP-1 medications in 2026.
The Compounding Pharmacy Crackdown: Who's Still Operating and Why | SourceGLP-1
June 03, 2026
Complete investigation into which compounding pharmacies are still legally operating post-crackdown.
Compounded vs Brand-Name Semaglutide: Safety Data Compared | SourceGLP-1
June 03, 2026
FDA testing found compounded semaglutide potency ranging 42-170% of labeled dose. FAERS reports 442 adverse events. Here's the complete safety comparison.
How Compounded GLP-1 Pricing Works Post-Shortage | SourceGLP-1
June 03, 2026
Current compounded GLP-1 pricing vs. brand-name cash-pay programs in 2026.
Compounded GLP-1 Pricing Map: What Every Provider Charges (May 2026) | SourceGLP-1
June 03, 2026
We compiled compounded and brand-name GLP-1 pricing from verified provider websites. Every option ranked from cheapest to most expensive.
Compounded GLP-1 Potency Variation: What Lab Testing Actually Shows | SourceGLP-1
June 03, 2026
Independent lab testing of compounded semaglutide found products ranging from 42% to 170% of labeled potency. Here's what the data reveals about quality variation.
Compounded GLP-1 Potency: What Testing Actually Reveals | SourceGLP-1
June 03, 2026
FDA testing data, Novo Nordisk analyses, and independent assays reveal wide potency variation in compounded semaglutide—from 0% to over 120% of labeled strength.
Celebrities Who've Confirmed GLP-1 Use (Updated List) | SourceGLP-1
June 03, 2026
Which celebrities have actually admitted to using Ozempic, Wegovy, or Mounjaro? We tracked down the direct quotes — no speculation, just confirmed statements.
CagriSema: The Combination-Therapy Evidence Review | SourceGLP-1
June 03, 2026
Evidence review of the CagriSema combination therapy trials and its competitive positioning vs tirzepatide.
CagriSema: Novo Nordisk's Next-Generation GLP-1/Amylin Combination | SourceGLP-1
June 03, 2026
CagriSema combines semaglutide with cagrilintide (amylin analog). Phase 3 results expected 2026, targeting ~25% weight loss. Full mechanism and trial analysis.
Is Byetta Still Available in 2026? Exenatide Status & Alternatives | SourceGLP-1
June 03, 2026
Byetta (exenatide) was discontinued by AstraZeneca in October 2024. A generic version exists from Amneal. Here's the current availability status and better GLP-1 alternatives in 20
Best Deals on Prescription Weight Loss Meds for New Patients in 2026 | SourceGLP-1
June 03, 2026
Every way to save on GLP-1 weight loss medications in 2026. Brand-name pills from $149/mo, compounded injectables from $146/mo, and new savings programs.
BALANCE Model: Medicare's GLP-1 Expansion Timeline | SourceGLP-1
June 03, 2026
Complete implementation timeline for the CMS BALANCE Model and expanded Medicare GLP-1 coverage.
The Amycretin Data Is In: Viking Therapeutics Phase 2 Results Decoded | SourceGLP-1
June 03, 2026
Viking Therapeutics' VK2735 (amycretin-type dual agonist) showed up to 14.7% weight loss in just 13 weeks. Here's what the Phase 2 data means for the GLP-1 pipeline.
The 600,000-Person Study That Just Changed Everything We Know About GLP-1s and Addiction | SourceGLP-1
June 03, 2026
A massive VA study found GLP-1 drugs reduce substance use disorders across opioids, cocaine, nicotine, alcohol, and cannabis by 15-25%. Here's what the data actually shows
503A vs 503B Compounding Pharmacies: Regulatory Differences Explained | Source GLP-1
June 03, 2026
State-regulated compounding pharmacy or FDA-regulated outsourcing facility? The structural difference shaped the entire compounded GLP-1 market — and now shapes what's legal post
503A vs 503B: The Complete Framework for GLP-1 Compounding | SourceGLP-1
June 03, 2026
Understand the FDA's 503A and 503B compounding designations. Learn how they affect your semaglutide and tirzepatide prescriptions, quality standards, and what certifications to loo
503A Pharmacies: The Last Legal Pathway for Compounded GLP-1s? | SourceGLP-1
June 03, 2026
The FDA's 503B proposal doesn't directly target 503A pharmacies. Here's why 503A compounding operates under different rules and what it means for patient
Danuglipron: The Rise and Fall of Pfizer's Oral GLP-1 — And What It Teaches Us | SourceGLP-1
May 26, 2026
Danuglipron: The Rise and Fall of Pfizer's Oral GLP-1 — And What It Teaches Us
Sprout Health GLP-1 Review: Cost, Medications & What to Expect in 2026 | SourceGLP-1
May 21, 2026
Sprout Health offers compounded semaglutide at $249/month and tirzepatide at $299/month with locked pricing at any dose. Full 2026 review covering cost, process, and legitimacy.
GobyMeds Review: $99/Month Semaglutide With No Membership Fees | SourceGLP-1
May 21, 2026
GobyMeds offers compounded semaglutide from $99/month and tirzepatide from $133/month with no membership, free consultation, and free overnight shipping. Full 2026 review.
GLP-1 vs Bariatric Surgery: Comparing Weight Loss, Cost & Recovery in 2026 | SourceGLP-1
May 21, 2026
How does GLP-1 medication compare to gastric bypass and sleeve gastrectomy? We compared weight loss outcomes, costs, risks, recovery time, and long-term data.
GLP-1 Slow Responders: Why It's Not Working and What to Try Next | SourceGLP-1
May 21, 2026
Not losing weight on GLP-1 medication? 10-15% of patients are slow or non-responders. Here's why it happens, what the research says, and evidence-based strategies to improve your r
CagriSema & SURMOUNT-5: The Next-Gen GLP-1 Trial Results Explained | SourceGLP-1
May 21, 2026
CagriSema produced 22.7% weight loss in REDEFINE 1. SURMOUNT-5 showed tirzepatide beats semaglutide head-to-head. What these trials mean for the future of obesity treatment.
EMA Safety Review: GLP-1 Drugs and Mental Health | SourceGLP-1
May 19, 2026
In 2023, the EMA launched a safety review of GLP-1 drugs and suicidal ideation. In 2024, they concluded: no causal link found. Here's the complete evidence, including the FDA's par
GLP-1 and Surgical Anesthesia: The Fasting Debate | SourceGLP-1
May 19, 2026
GLP-1 drugs slow gastric emptying, raising concerns about aspiration during anesthesia. The ASA updated its guidelines in 2023. Here's what surgeons and anesthesiologists need to k
GLP-1 and Gallbladder Events: Quantifying the Risk | SourceGLP-1
May 19, 2026
Rapid weight loss from any cause increases gallstone risk. GLP-1 drugs are no exception. Here's the actual incidence data from STEP, SURMOUNT, and SELECT trials, the mechanism, and
Medicare BALANCE Model: What Changes for GLP-1 Coverage | SourceGLP-1
May 18, 2026
CMS announced the BALANCE Model in December 2025 to expand GLP-1 access through Medicare and Medicaid. Copays capped at $50/month. Medicaid launch expected May 2026, Medicare Part
When Do GLP-1 Generics Arrive? The Complete Patent Cliff Analysis | SourceGLP-1
May 18, 2026
Semaglutide patents expire December 2031, tirzepatide January 2036. Generic liraglutide arrived in 2024. Full patent landscape, settlement details, biosimilar pathway, and internat
GLP-1 for Adolescents: What STEP TEENS Showed | SourceGLP-1
May 17, 2026
STEP TEENS: semaglutide produced a 17% BMI reduction in adolescents aged 12-17 with obesity. 45% dropped below the clinical obesity threshold. NEJM 2022. Complete trial data and pe
International GLP-1 Pricing: Why Americans Pay 10× More | SourceGLP-1
May 17, 2026
Wegovy costs $1,349/month in the US, under $200 in Germany, and as little as $40 in India. Here's the country-by-country pricing breakdown and the structural reasons behind the gap
GLP-1 Insurance Coverage: The 2026 State-by-State Landscape | SourceGLP-1
May 17, 2026
Insurance coverage for GLP-1 weight loss drugs varies dramatically by state, employer, and plan type. Some states mandate coverage; many Medicaid programs still exclude anti-obesit
GLP-1 Anti-Inflammatory Effects: The Evidence Beyond Weight Loss | SourceGLP-1
May 16, 2026
Meta-analysis of 40 RCTs: GLP-1 drugs significantly reduce CRP and TNF-alpha vs placebo and other diabetes drugs. Only 20-60% of CRP reduction is explained by weight loss. Complete
Pemvidutide: The GLP-1/Glucagon Drug Targeting Both Weight and Liver Disease | SourceGLP-1
May 16, 2026
Altimmune's pemvidutide is a GLP-1/glucagon dual agonist designed specifically for MASH and obesity. Phase 2 data showed 10-15% weight loss and significant liver fat reduction at 4
GLP-1 and PCOS: What the Clinical Evidence Shows | SourceGLP-1
May 16, 2026
Polycystic ovary syndrome affects 10% of women. GLP-1 drugs improve insulin resistance, reduce androgens, restore ovulation, and produce weight loss. Here's the evidence from clini
Survodutide: Boehringer's GLP-1/Glucagon Dual Agonist Improved MASH in 83% of Patients | SourceGLP-1
May 15, 2026
Survodutide Phase 2 NEJM data: 83% MASH improvement, 87% liver fat reduction, 64.5% fibrosis improvement. Glucagon mechanism explained. Phase 3 trials for obesity and liver disease
Oral Semaglutide: The OASIS Trial Program That Made the GLP-1 Pill Real | SourceGLP-1
May 15, 2026
The FDA approved oral Wegovy in December 2025 based on OASIS 4 data: 16.6% weight loss at 64 weeks. Complete trial results, comparisons to injectable, and what it means for patient
GLP-1 and Bone Density: Does Rapid Weight Loss Put Your Skeleton at Risk? | SourceGLP-1
May 14, 2026
Rapid weight loss reduces bone density, but major GLP-1 trials show no increase in fracture events. The SELECT trial, AAOS 2026 data, and what the evidence actually says about bone
CagriSema: Why Novo Added Amylin to GLP-1 — and Got 22.7% Weight Loss | SourceGLP-1
May 14, 2026
CagriSema combines semaglutide with cagrilintide (amylin analog). REDEFINE 1: 22.7% weight loss at 68 weeks, 60% lost 20%+. NDA filed December 2025. Complete data breakdown.
SURMOUNT-5: Tirzepatide vs. Semaglutide Head-to-Head — The Complete Data | SourceGLP-1
May 13, 2026
The first direct comparison trial: tirzepatide lost 20.2% vs. semaglutide's 13.7% at 72 weeks. NEJM-published SURMOUNT-5 data, secondary endpoints, safety, and what the numbers act
Retatrutide: The Triple Agonist That Hit 24.2% Weight Loss in Phase 2 | SourceGLP-1
May 13, 2026
Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 data: 24.2% body weight loss at 48 weeks, 86% achieved normal liver fat. Here's every number from the
FLOW Trial: Semaglutide Reduced Kidney Disease Events by 24% | SourceGLP-1
May 12, 2026
The FLOW trial is the first dedicated kidney outcomes trial for a GLP-1 drug. Semaglutide cut major kidney events by 24%, cardiovascular death by 29%, and was stopped early for eff
FDA's 503B Exclusion: The April 2026 Move That Ends Large-Scale GLP-1 Compounding | SourceGLP-1
May 12, 2026
On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. Here's what the 41-page Federal Register notice actually says —
ESSENCE Trial: Semaglutide Resolved Fatty Liver Disease in 62.9% of Patients | SourceGLP-1
May 11, 2026
The Phase 3 ESSENCE trial showed semaglutide 2.4 mg resolved MASH in 62.9% of patients and improved liver fibrosis in 37%. Published in NEJM April 2025. FDA granted Priority Review
GLP-1 Cost in 2026: Every Option from $50 to $1,349 per Month | SourceGLP-1
May 09, 2026
Complete GLP-1 pricing guide for 2026: Medicare Bridge at $50/mo, oral Wegovy at $149, compounded options, insurance, and manufacturer savings programs. Every price sourced.
The Ozempic Plateau: Why Weight Loss Stalls and What the Data Says | SourceGLP-1
May 09, 2026
GLP-1 weight loss plateaus are normal and documented in every major trial. Here's when they happen, why, and evidence-based strategies for breaking through stalls.
GLP-1 Medications and Testosterone: What the Clinical Evidence Shows | SourceGLP-1
May 09, 2026
Systematic reviews confirm GLP-1 drugs increase testosterone in obese men by 1.39 ng/mL on average. How it works, fertility implications, and every major study explained.
GLP-1 and Smoking Cessation: What Semaglutide Could Mean for Quitting | SourceGLP-1
May 09, 2026
222,942-patient study shows semaglutide users have 32% fewer tobacco-related medical encounters. Active trials, the dopamine mechanism, and what it means for smokers.
Who Qualifies for GLP-1 Medications? Complete Eligibility Criteria for 2026 | SourceGLP-1
April 24, 2026
Complete GLP-1 eligibility guide: BMI requirements, qualifying conditions, Medicare coverage starting July 2026, insurance criteria, and who does not qualify. Every threshold expla
GLP-1 Medications and Depression: What the Research Actually Shows | SourceGLP-1
April 24, 2026
Does semaglutide help or worsen depression? A 100,000-person Swedish study, FDA safety reviews, and every major finding on GLP-1 medications and mental health — sourced and expla
No articles found matching your search.